Moffitt Cancer Center 19th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies 2024

Topics:

• FINAL.Heme-Conference-AGENDA-2024-v21.pdf
• Hot Off the Press Lymphoid Diseases.mp4
• Hot Off the Press Myeloid Diseases.mp4
• Hot Off the Press Plasma Cell Dyscrasias.mp4
• Lymphoid Malignancies Debate Harnessing the Immune System to Manage Relapsed Refractory Diffuse Large B Cell Lymphom No.mp4
• Lymphoid Malignancies Debate Harnessing the Immune System to Manage Relapsed Refractory Diffuse Large B Cell
• Lymphom Yes.mp4
• Lymphoid Malignancies Interactive Case Discussion Optimal Management of Patients with CLL.mp4
• Lymphoid Malignancies State of the Art Frontline Treatment of Advanced Stage Hodgkin Lymphoma.mp4
• Multiple Myeloma Debate Response-adapted approach to transplant in newly diagnosed MM are we there yet No.mp4
• Multiple Myeloma Debate Response-adapted approach to transplant in newly diagnosed MM are we there yet Yes.mp4
• Multiple Myeloma Interactive Case Discussion Optimal timing of CART-cell therapy in myeloma.mp4
• Multiple Myeloma State of the Art Bi-specifics antibodies in myeloma Which How When.mp4
• Myeloid Malignancies Debate- Worst of the worst- Should we transplant patients with p53 mutant MDS or AML Yes.mp4
• Myeloid Malignancies Interactive Case Discussion- Optimal use of targeted therapy for the elderly or unfit AML patient.mp4
• Myeloid Malignancies State of the Art- Making Sense of the New Classification Systems for MDS.mp4

Clinical Breakthroughs and Challenges
in Hematologic Malignancies
January 27, 2024
AGENDA

• 7:00-8:00 am Breakfast and Registration
  8:00-8:05 am Welcome and Introductions
  SESSION Lymphoid Malignancies — Moderator: Celeste Bello, MD
  8:05-8:30 am State of the Art: Frontline Treatment of Advanced Stage Hodgkin Lymphoma
  Hayder Saeed, MD
  8:30-8:55 am Interactive Case Discussion: Optimal Management of Patients with CLL
  Javier Pinilla, MD
  8:55-9:25 am Debate: Harnessing the Immune System to Manage Relapsed/Refractory Diffuse Large B Cell Lymphoma: Are
  Bispecific Antibodies Superior to CAR T Cell Therapy?
  Yes: Julio Chavez, MD | No: Aleksandr Lazaryan, MD, MPH, PhD
  9:25-9:30 am Audience Interaction — Vote Now!
  9:30-9:55 am Break and Exhibits
  SESSION Myeloid Malignancies — Moderator: Eric Padron, MD
  9:55-10:25 am State of the Art: Making Sense of the New Classification Systems for MDS
  Rami Komrokji, MD
  10:25-10:55 am Interactive Case Discussion: Optimal use of targeted therapy for the elderly or unfit AML patient
  Onyee Chan, MD
  11:00-11:30 am Debate: Worst of the worst: Should we transplant patients with p53 mutant MDS or AML
  Yes: Hany Elmariah, MD, MS | No: David Sallman, MD
  11:25-11:30 am Audience Interaction — Vote Now!
  11:30 am-12:45 pm Networking Lunch and Exhibits
  SESSION Multiple Myeloma — Moderator: Melissa Alsina, MD
  12:45-1:10 pm State of the Art: Bi-specifics antibodies in myeloma: Which? How? When?
  Ariel Grajales-Cruz, MD
  1:10-1:35 pm Interactive Case Discussion: Optimal timing of CART-cell therapy in myeloma
  Ciara Freeman, MD
  1:35-2:05 pm Debate: Response-adapted approach to transplant in newly diagnosed MM: are we there yet?
  Yes: Ken Shain, MD | No: Omar Castañeda-Puglianini, MD
  2:05-2:10 pm Audience Interaction — Vote Now!
  2:10-2:35 pm Break and Exhibits
  2:35-2:45 pm Raffle Winners Announced (you must be present to win)
  SESSION Hot Off the Press! — Moderator: Jeffrey Lancet, MD
  2:45-3:15 pm Myeloid Diseases
  Presenter: Andrew Kuykendall, MD
  Panel: Rami Komrokji, MD; Onyee Chan, MD; David Sallman, MD
  3:15-3:45 pm Lymphoid Diseases
  Presenter: Bijal Shah, MD
  Panel: Hayder Saeed, MD; Julio Chavez, MD; Javier Pinilla, MD; and Aleksandr Lazaryan, MD
  3:45-4:15 pm Plasma Cell Dyscrasias
  Presenter: Rachid Baz, MD
  Panel: Melissa Alsina, MD; Kenneth Shain, MD, PhD; Ariel Grajales-Cruz, MD
  4:15-4:30 pm Closing RemarkS